Skip to content

Ironwood Pharmaceuticals

US · IRWD #3609 by market cap
4.70 -0.01 -0.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 4.66 -1.06%
After-hours 4.60 -2.13%
4.873.224.702026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IRWD?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +30.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 9.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation A

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 5.2x Better than 96%
Forward P/E 3.6x Better than 99%
Price / Sales 2.0x Better than 57%
P/E vs own 5-yr range 55th pctl Better than 55%
Growth F

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -10.3% Better than 6%
Net income CAGR (3Y) -48.4% Better than 4%
Free cash flow CAGR (3Y) -22.6% Better than 16%
Profitability B-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin 40.1% Better than 95%
Net margin 8.1% Better than 54%
Return on equity -654.9% Better than 1%
Return on invested capital -139.2% Better than 1%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 9.6% Better than 90%
6-month return 19.9% Better than 83%
12-month return (ex latest month) 13.0% Better than 50%
Distance below 52-week high 18.7% Better than 63%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.1x Better than 26%
Debt to assets 150.6% Better than 1%
Interest coverage 3.1x Better than 46%
Free cash flow / net income 528.8% Better than 93%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.69%
1M +29.48%
3M +13.53%
6M +19.90%
YTD +39.47%
1Y +48.26%
3Y -50.58%
5Y -59.83%

Key statistics

Price & volume

Prev close
4.71
Open
4.66
Day range
4.65 - 4.87
Avg price
4.73
Volume
3.02M
Turnover
14.28M
Amplitude
4.67%
52-week range
2.95 - 5.78

Valuation

P/E
31.33
P/E (TTM)
5.22
P/B
-8.01
EPS
0.15
Net profit
24.83M
Net assets
-97.18M

Share structure

Market cap
778.09M
Float cap
639.23M
Shares out
165.55M
Float shares
136.01M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 62% of range
2.95 5.78

18.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-5.44M net over the window

Short interest

Shares short
14.86M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Ironwood Pharmaceuticals (IRWD)?

Ironwood Pharmaceuticals last traded at 4.70. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Ironwood Pharmaceuticals's market cap?

About 778.09M.

What is the P/E ratio of Ironwood Pharmaceuticals?

The trailing twelve-month P/E is 5.22. The Valuation tab shows it against the stock's own five-year range.

Does Ironwood Pharmaceuticals pay a dividend?

Ironwood Pharmaceuticals does not currently pay a regular dividend.

Is Ironwood Pharmaceuticals a buy according to analysts?

The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 6.00, which implies 27.7% upside from the current price. This is not investment advice.

What is Ironwood Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Ironwood Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:01:04 · For reference only, not investment advice and not tailored to your situation.

Ironwood Pharmaceuticals discussion 0 comments

Add a comment